The purpose of this study is to trial potential new treatment for Chronic Hepatitis B.
Chronic hepatitis B is a common chronic infectious disease that is highly infective, has poor prognosis, and is difficult to cure. Chronic HBV infection is a worldwide public health problem that affects approximately 257 million patients worldwide.
This drug is developed as a novel antibody targeting Hepatitis B administered as a subcutaneous injection.
While hepatitis B immunisation has contributed to the reduction of new cases, treatment options for the large number of patients with chronic hepatitis B are limited because of adverse reactions to existing treatments, the ability of HBV to resist existing HBV drugs, and the body’s inability to completely clear HBV.
The trial has been approved by an independent ethics committee and participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!